Rank |
Status |
Study |
1 |
Recruiting
|
Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease
Condition: |
Crohn's Disease |
Interventions: |
Drug: Azithromycin + Metronidazole; Drug: Metronidazole |
Outcome Measures: |
Response rate at 8 weeks defined as a drop in PCDAI (Pediatric Crohn's Disease Activity Index ) of at least 12.5 points (or remission without steroids, intention to treat principle); Normalization of CRP ( CRP ≤0.5 mg/dL).; Fecal calprotectin at 8 weeks . |
|
2 |
Not yet recruiting
|
Study to Determine the Equivalence of Three Products Containing Metronidazole Benzoate.
Condition: |
Bacterial Infections |
Interventions: |
Drug: Metronidazole benzoate; Drug: Flagyl 125 mg/5 ml oral suspension; Drug: Flagyl 400 mg Tablets |
Outcome Measures: |
Plasma concentration time profiles under the curve (AUC); Maximum concentration (Cmax); Time to maximum concentration (Tmax); Elimination rate constant (Kel); Terminal half life (t1/2); Number of participants with Adverse Events |
|
3 |
Recruiting
|
Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies
Conditions: |
Abnormal Vaginal Flora; Clindamycin Vs Metronidazole; High Risk Pregnancies for Preterm Labor |
Interventions: |
Drug: Clindamycin; Drug: Metronidazole |
Outcome Measures: |
To compare the efficacy between oral Clindamycin Vs Metronidazole in the eradication of abnormal vaginal flora; The prevalence of adverse effects; The prevalence of late abortions and preterm deliveries; Assessing the correlation between Nugent score , physical examination and Ph indicators |
|
4 |
Recruiting
|
BASIC (Boric Acid, Alternate Solution for Intravaginal Colonization) Study
Condition: |
Bacterial Vaginosis |
Interventions: |
Drug: Gelatin; Drug: Boric acid; Drug: Metronidazole |
Outcome Measures: |
Effectiveness of treatment of intravaginal boric acid and metronidazole at 1 week and 30 days post-treatment will be measured as absence of symptoms or negative vaginal swab (Nugent score less than 7) if symptoms are present for BV.; If during the 10 days of treatment of intravaginal boric acid and metronidazole the patient discontinues the treatment because of side effects or complained of intolerable side effects this will be considered a treatment failure for safety. |
|
5 |
Recruiting
|
Role of N-Acetylcysteine in Treatment of Bacterial Vaginosis
Condition: |
Bacterial Vaginosis |
Interventions: |
Drug: N-Acetyl cysteine; Drug: Metronidazole + N-Acetyl cysteine; Drug: metronidazole |
Outcome Measures: |
recovery of BV; prevention of recurrence |
|
6 |
Unknown †
|
Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy
Condition: |
Bacterial Infection Due to Helicobacter Pylori (H. Pylori) |
Interventions: |
Drug: 10RAC+acetylcystein; Drug: 10RAC+metronidazole |
Outcome Measures: |
Re-eradication rate; Influence of Participant's CYP2C19 genotype on re-eradication rate |
|
7 |
Unknown †
|
Inflammation and Treatment of Bacterial Vaginosis Near Term
Condition: |
Bacterial Vaginosis |
Interventions: |
Drug: Metronidazole; Drug: Placebo |
Outcome Measure: |
Levels of Interleukins 1 and 6 as well as Tumor Necrosis Factor Alpha |
|
8 |
Recruiting
|
Impact of Oral Antibiotic Treatment on C. Difficile
Conditions: |
C. Difficile; Diarrhea; Enterocolitis |
Interventions: |
Drug: Fidaxomicin; Drug: Metronidazole; Drug: Vancomycin |
Outcome Measures: |
Change in variation of the profile of C. difficile isolated from specific body sites of a patient with microbiology-proven CDAD; Change in variation in the profile of C. difficile isolated from targeted surfaces in a hospital; Extent and quantity of C. difficile shedding, colonization and environmental contamination in patients who received oral fidaxomicin vs. oral metronidazole or vancomycin; Duration of diarrhea that were positive for CDAD |
|
9 |
Unknown †
|
Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses
Condition: |
Abscess, Intra-Abdominal |
Intervention: |
Drug: Moxifloxacin/Metronidazole or Piperacillin/Tazobactam |
Outcome Measures: |
Clinical success / failure rate at the Test-of-Cure visit; Clinical + Bacteriological response at End-of-Treatment-visit; Time to discharge from hospital; Course of disease on the basis of clinical and laboratory parameters; safety and tolerability of the study medication; cost effectiveness of treatment regimes |
|
10 |
Recruiting
|
Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy
Condition: |
Helicobacter Pylori Infection |
Interventions: |
Drug: pantoprazole, amoxicillin, clarithromycin, metronidazole; Drug: pantoprazole, amoxicillin, clarithromycin, metronidzole |
Outcome Measure: |
Comparison of the eradications rates of sequential therapy versus concomitant therapy of treatment of Helicobacter pylori infection in Korea. |
|
11 |
Recruiting
|
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
Condition: |
Complicated Intra-Abdominal Infection |
Interventions: |
Drug: CAZ-AVI; Drug: Metronidazole; Drug: Meropenem |
Outcome Measures: |
Clinical Cure as Measured by proportion of patients meeting cure criteria in the microbiological modified Intent-To-Treat analysis set.; The proportion of patients with clinical cure in the microbiologically evaluable and extended microbiologically evaluable analysis set; The proportion of patients with clinical cure in the microbiological modified intent-to-treat, microbiologically evaluable, and extended microbiologically evaluable analysis sets; The proportion of patients with clinical cure in the clinically evaluable analysis set.; The proportion of patients with a favorable per-patient microbiological response in the microbiological modified intent to treat, microbiologically evaluable, and extended microbiologically evaluable analysis sets; The proportion of favorable per-pathogen microbiological response in the microbiological modified intent to treat, microbiologically evaluable, and extended microbiologically evaluable analysis sets; The favorable per-pathogen microbiologic response by minimum inhibitory concentration (MIC) categories in the microbiological modified intent to treat, microbiologically evaluable, and extended microbiologically evaluable analysis sets; Favorable per-patient clinical response & microbiological response for patients infected with ceftazidime-resistant pathogens in microbiological modified intent to treat, microbiologically evaluable & extended microbiologically evaluable analysis sets; Proportion of patients with favorable per-pathogen microbiological response for patients infected with ceftazidime-resistant pathogens in microbiological modified ITT, microbiologically evaluable and extended microbiologically evaluable analysis sets; The time to first defervescence in the clinically evaluable, microbiologically evaluable, and extended microbiologically evaluable analysis sets for patients who have fever at study entry; The safety and tolerability by incidence and severity of adverse events and serious adverse events, vital signs, clinical laboratory tests, ECGs and physical exams.; Pharmacokinetics: maximum concentration (Cmax), minimum concentration, area under the plasma concentration time curve at steady state, and terminal half-life |
|
12 |
Recruiting
|
Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections
Condition: |
Complicated Intra-abdominal Infection |
Interventions: |
Drug: Ceftazidime-avibactam; Drug: metronidazole; Drug: Meropenem |
Outcome Measures: |
The proportion of patients with clinical cure in the clinically evaluable analysis set; The proportion of patients with clinical cure in the microbiologically evaluable, extended microbiologically evaluable and microbiological modified intent-to-treat analysis sets; The proportion of patients with a favorable per-patient microbiological response in the microbiological modified intent to treat, microbiologically evaluable and extended microbiologically evaluable analysis sets; The proportion of favorable per-pathogen microbiological response in the microbiological modified intent to treat, microbiologically evaluable and extended microbiologically evaluable analysis sets; The favorable per-pathogen microbiologic response by minimum inhibitory concentration categories in the microbiological modified intent to treat, microbiologically evaluable and extended microbiologically evaluable analysis sets; Favorable clinical response and favorable per-patient microbiological response for patients infected with ceftazidime-resistant pathogens in the microbiological modified intent to treat and (extended) microbiologically evaluable analysis sets; The proportion of patients with a favorable per-pathogen microbiological response for patients infected with ceftazidime-resistant pathogens in the microbiological modified intent to treat and (extended) microbiologically evaluable analysis sets; The time to first defervescence in the clinically evaluable, microbiologically evaluable and extended microbiologically evaluable analysis sets for patients who have fever at study entry; Safety and tolerability by incidence and severity of adverse events and serious adverse events, exposure, mortality, reasons for discontinuations of study therapy, vital signs, laboratory tests, electrocardiogram parameters and physical exams |
|
13 |
Unknown †
|
Effects of the Variation in the Time of Systemic Administration of Metronidazole and Amoxicillin Associated to the Non-surgical Therapy of Chronic Periodontitis.
Conditions: |
Chronic Periodontitis; Clinical and Microbiological Effects |
Intervention: |
Drug: Administration of Metronidazole plus Amoxicillin |
Outcome Measures: |
- Mean change in clinical attachment level (CAL); - Mean change in probing pocket depths (PD) |
|
14 |
Recruiting
|
The Use of Erythritol Powder and Metronidazole Gel for the Non-surgical Treatment of Periodontitis
Condition: |
Periodontal Pocket |
Interventions: |
Drug: metronidazole gel; Procedure: ultrasonics; Procedure: erythritol; Drug: placebo |
Outcome Measures: |
Probing pocket Depth change; Bleeding on Probing change; Clinical Attachment level change |
|
15 |
Not yet recruiting
|
Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy
Conditions: |
Prostate Cancer; Prostatic Neoplasms; Neoplasms, Prostate |
Interventions: |
Biological: PROSTVAC-V/TRICOM; Biological: PROSTVAC-F/TRICOM |
Outcome Measures: |
Changes from baseline to after surgery of CD4 and CD8 cell infiltrates; Change in peripheral PSA-specific T cells; Any intraprostatic Treg cell infiltration with CD4+FOX-P3 staining; Any PSA changes secondary to vaccination; Any MRI changes secondary to vaccination |
|
16 |
Unknown †
|
The Impact of Obesity on Nonsurgical Periodontal Therapy
Conditions: |
Periodontitis; Periodontal Diseases; Obesity |
Interventions: |
Drug: Metronidazole; Drug: Placebo; Procedure: Scaling and root planning |
Outcome Measures: |
Probing depth; Attachment level |
|
17 |
Recruiting
|
Concomitant Therapy of H. Pylori
Condition: |
Gastritis, Gastric Ulcer, and Duodenal Ulcer |
Intervention: |
Drug: amoxicillin, clarithromycin, metronidazole, rabeprazole |
Outcome Measure: |
Evaluation of the efficacy of concomitant therapy for eradication of Helicobacter pylori |
|
18 |
Recruiting
|
Antibiotic Safety (SCAMP)
Condition: |
Complicated Intra Abdominal Infections |
Interventions: |
Drug: ampicillin and metronidazole and gentamicin; Drug: ampicillin and gentamicin and clindamycin; Drug: gentamicin and Piperacillin- tazobactam; Drug: standard of care antibiotics and metronidazole |
Outcome Measures: |
Death; Number of participants with therapeutic success at Day 30 and Day 90 |
|
19 |
Recruiting
|
Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
Condition: |
Prostate Cancer |
Interventions: |
Biological: PROSTVAC-F/TRICOM; Biological: PROSTVAC-V/TRICOM; Drug: Enzalutamide (Xtandi) |
Outcome Measures: |
Decrease in tumor re-growth rate; Immune response; Determine impact on PSA |
|
20 |
Recruiting
|
Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population
Conditions: |
Vaginosis, Bacterial; Infertility; Miscarriage |
Interventions: |
Drug: Metronidazole; Drug: Placebo |
Outcome Measures: |
Biochemical Pregnancy Rate (Positive Pregnancy Test); Pregnancy Rate (Pregnancy Visible on Ultrasound); Miscarriage Rate (Loss of a Clinically Recognized Pregnancy); Infectious Morbidity (i.e. Chorioamnionitis, Neonatal Sepsis) |
|